148 related articles for article (PubMed ID: 22820099)
1. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling.
Wang K; Zhuang Y; Liu C; Li Y
Arch Biochem Biophys; 2012 Oct; 526(1):38-43. PubMed ID: 22820099
[TBL] [Abstract][Full Text] [Related]
2. Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity.
Qiao H; Saulnier R; Patryzkat A; Rahimi N; Raptis L; Rossiter J; Tremblay E; Elliott B
Cell Growth Differ; 2000 Feb; 11(2):123-33. PubMed ID: 10714768
[TBL] [Abstract][Full Text] [Related]
3. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma.
Coltella N; Manara MC; Cerisano V; Trusolino L; Di Renzo MF; Scotlandi K; Ferracini R
FASEB J; 2003 Jun; 17(9):1162-4. PubMed ID: 12709413
[TBL] [Abstract][Full Text] [Related]
4. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
5. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
[TBL] [Abstract][Full Text] [Related]
6. Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT.
Zhou HH; Chen L; Liang HF; Li GZ; Zhang BX; Chen XP
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110775
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the met receptor tyrosine kinase signaling enhances the chemosensitivity of glioma cell lines to CDDP through activation of p38 MAPK pathway.
Lou X; Zhou Q; Yin Y; Zhou C; Shen Y
Mol Cancer Ther; 2009 May; 8(5):1126-36. PubMed ID: 19435873
[TBL] [Abstract][Full Text] [Related]
9. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
Maulik G; Madhiwala P; Brooks S; Ma PC; Kijima T; Tibaldi EV; Schaefer E; Parmar K; Salgia R
J Cell Mol Med; 2002; 6(4):539-53. PubMed ID: 12611639
[TBL] [Abstract][Full Text] [Related]
10. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
[TBL] [Abstract][Full Text] [Related]
11. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways.
Bowers DC; Fan S; Walter KA; Abounader R; Williams JA; Rosen EM; Laterra J
Cancer Res; 2000 Aug; 60(15):4277-83. PubMed ID: 10945642
[TBL] [Abstract][Full Text] [Related]
12. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair.
Fan S; Ma YX; Gao M; Yuan RQ; Meng Q; Goldberg ID; Rosen EM
Mol Cell Biol; 2001 Aug; 21(15):4968-84. PubMed ID: 11438654
[TBL] [Abstract][Full Text] [Related]
13. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
14. c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.
Tang MK; Zhou HY; Yam JW; Wong AS
Neoplasia; 2010 Feb; 12(2):128-38. PubMed ID: 20126471
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation.
Grotegut S; Kappler R; Tarimoradi S; Lehembre F; Christofori G; Von Schweinitz D
Int J Oncol; 2010 May; 36(5):1261-7. PubMed ID: 20372801
[TBL] [Abstract][Full Text] [Related]
16. The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway.
Wang D; Saga Y; Sato N; Nakamura T; Takikawa O; Mizukami H; Matsubara S; Fujiwara H
Int J Oncol; 2016 Jun; 48(6):2303-9. PubMed ID: 27082119
[TBL] [Abstract][Full Text] [Related]
17. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
[TBL] [Abstract][Full Text] [Related]
18. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
Li Y; Huang X; Zhang J; Li Y; Ma K
Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
[TBL] [Abstract][Full Text] [Related]
19. Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells.
Shi MD; Liao YC; Shih YW; Tsai LY
Phytomedicine; 2013 Jun; 20(8-9):743-52. PubMed ID: 23537747
[TBL] [Abstract][Full Text] [Related]
20. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.
Peng DJ; Wang J; Zhou JY; Wu GS
Biochem Biophys Res Commun; 2010 Apr; 394(3):600-5. PubMed ID: 20214883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
